Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO.2 TO FORM S-1 - ARATANA THERAPEUTICS, INC. | d599715ds1a.htm |
| EX-10.10 - EX-10.10 - ARATANA THERAPEUTICS, INC. | d599715dex1010.htm |
| EX-10.8(A) - EX-10.8(A) - ARATANA THERAPEUTICS, INC. | d599715dex108a.htm |
| EX-1.1 - EX-1.1 - ARATANA THERAPEUTICS, INC. | d599715dex11.htm |
| EX-23.2 - EX-23.2 - ARATANA THERAPEUTICS, INC. | d599715dex232.htm |
| EX-5.1 - EX-5.1 - ARATANA THERAPEUTICS, INC. | d599715dex51.htm |
| EX-5.2 - EX-5.2 - ARATANA THERAPEUTICS, INC. | d599715dex52.htm |
| EX-23.1 - EX-23.1 - ARATANA THERAPEUTICS, INC. | d599715dex231.htm |
Exhibit 23.3
CONSENT OF INDEPENDENT AUDITORS
We consent to the use in this Amendment No. 2 to the Registration Statement on Form S-1 of Aratana Therapeutics Inc. of our report dated January 13, 2014 related to the financial statements of Okapi Sciences NV (the “Company”) as of and for the years ended December 31, 2012 and 2011 and from December 20, 2007 (date of inception) to December 31, 2012 (which report expresses an unmodified opinion on the financial statements and includes as explanatory paragraph indicating that: (a) the financial statements have been prepared assuming that the Company will continue as a going concern, (b) as discussed in Note 1 to the financial statements, the Company devotes substantially all of its efforts to research and development and has incurred losses since inception, (c) such condition raises substantial doubt about its ability to continue as a going concern, and (d) financial statements do not include any adjustments that might result from the outcome of the uncertainty) appearing in the prospectus, which is part of this Registration Statement, and to the reference to us under the heading “Experts” in such prospectus.
Diegem, Belgium
January 28, 2014
DELOITTE Bedrijfsrevisoren / Reviseurs d’Entreprises
BV o.v.v.e. CVBA / SC s.f.d. SCRL
Represented by
| /s/ Gert Vanhees |
/s/ Koen Neijens | |||||
| Gert Vanhees |
Koen Neijens |